These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 27574003)

  • 1. Genistein targets the cancerous inhibitor of PP2A to induce growth inhibition and apoptosis in breast cancer cells.
    Zhao Q; Zhao M; Parris AB; Xing Y; Yang X
    Int J Oncol; 2016 Sep; 49(3):1203-10. PubMed ID: 27574003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.
    Laine A; Sihto H; Come C; Rosenfeldt MT; Zwolinska A; Niemelä M; Khanna A; Chan EK; Kähäri VM; Kellokumpu-Lehtinen PL; Sansom OJ; Evan GI; Junttila MR; Ryan KM; Marine JC; Joensuu H; Westermarck J
    Cancer Discov; 2013 Feb; 3(2):182-97. PubMed ID: 23306062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
    Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
    Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
    Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
    Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cucurbitacin B reverses multidrug resistance by targeting CIP2A to reactivate protein phosphatase 2A in MCF-7/adriamycin cells.
    Cai F; Zhang L; Xiao X; Duan C; Huang Q; Fan C; Li J; Liu X; Li S; Liu Y
    Oncol Rep; 2016 Aug; 36(2):1180-6. PubMed ID: 27350399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
    Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
    Yu HC; Chen HJ; Chang YL; Liu CY; Shiau CW; Cheng AL; Chen KF
    Biochem Pharmacol; 2013 Feb; 85(3):356-66. PubMed ID: 23178652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancerous inhibitor of protein phosphatase 2A contributes to human papillomavirus oncoprotein E7-induced cell proliferation via E2F1.
    Zhang W; Chen H; Chen Y; Liu J; Wang X; Yu X; Chen JJ; Zhao W
    Oncotarget; 2015 Mar; 6(7):5253-62. PubMed ID: 25650660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis.
    Lin X; Gao M; Zhang A; Tong J; Zhang X; Su Q; Yang Z; Gao H; Jiang G
    Life Sci; 2019 Dec; 239():117074. PubMed ID: 31751585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
    Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
    Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genistein Decreases APP/tau Phosphorylation and Ameliorates Aβ Overproduction Through Inhibiting CIP2A.
    Shentu YP; Hu WT; Liang JW; Liuyang ZY; Wei H; Qun W; Wang XC; Wang JZ; Westermarck J; Liu R
    Curr Alzheimer Res; 2019; 16(8):732-740. PubMed ID: 31470788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.
    Lucas CM; Harris RJ; Holcroft AK; Scott LJ; Carmell N; McDonald E; Polydoros F; Clark RE
    Leukemia; 2015 Jul; 29(7):1514-23. PubMed ID: 25765543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
    Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
    Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
    Yu HC; Hung MH; Chen YL; Chu PY; Wang CY; Chao TT; Liu CY; Shiau CW; Chen KF
    Cell Death Dis; 2014 Jul; 5(7):e1359. PubMed ID: 25077545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase in CIP2A expression is associated with doxorubicin resistance.
    Choi YA; Park JS; Park MY; Oh KS; Lee MS; Lim JS; Kim KI; Kim KY; Kwon J; Yoon DY; Moon EY; Yang Y
    FEBS Lett; 2011 Mar; 585(5):755-60. PubMed ID: 21241697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of CIP2A in estrogen depletion-resistant breast cancer cells treated with low-dose everolimus.
    Nishio E; Hayashi T; Akaza M; Hisatomi Y; Hikichi M; Fujii T; Utsumi T; Harada N; Shimono Y
    FEBS Open Bio; 2020 Oct; 10(10):2072-2080. PubMed ID: 32810922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p90/CIP2A mediates breast cancer cell proliferation and apoptosis.
    Liu X; Peng B; Li Y; Lei N; Li W; Zhang JY
    Mol Biol Rep; 2014 Nov; 41(11):7471-8. PubMed ID: 25086622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.
    Khanna A; Kauko O; Böckelman C; Laine A; Schreck I; Partanen JI; Szwajda A; Bormann S; Bilgen T; Helenius M; Pokharel YR; Pimanda J; Russel MR; Haglund C; Cole KA; Klefström J; Aittokallio T; Weiss C; Ristimäki A; Visakorpi T; Westermarck J
    Cancer Res; 2013 Nov; 73(22):6757-69. PubMed ID: 24072747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells.
    Liu CY; Huang TT; Huang CT; Hu MH; Wang DS; Wang WL; Tsai WC; Lee CH; Lau KY; Yang HP; Chen MH; Shiau CW; Tseng LM; Chen KF
    Eur J Cancer; 2017 Feb; 72():112-123. PubMed ID: 28027514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.